Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway Corrigendum in /10.3892/mmr.2021.12547

Yao,Jiamei; Fang,Xia; Zhang,Cui; Yang,Yushu; Wang,Dongsheng; Chen,Qiong; Zhong,Guangwei

doi:10.3892/mmr.2020.11726

Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway

Corrigendum in: /10.3892/mmr.2021.12547

Authors:
- Jiamei Yao
- Xia Fang
- Cui Zhang
- Yushu Yang
- Dongsheng Wang
- Qiong Chen
- Guangwei Zhong
View Affiliations

Affiliations: Department of International Medical Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China, Department of Integrated Traditional Chinese and Western Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: November 24, 2020 https://doi.org/10.3892/mmr.2020.11726
Article Number: 89
Copyright: © Yao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Notch signaling pathway participates in pulmonary artery smooth muscle cell (PASMC) proliferation and apoptosis. Astragaloside IV (AS‑IV) is an effective antiproliferative treatment for vascular diseases. The present study aimed to investigate the protective effects and mechanisms underlying AS‑IV on hypoxia‑induced PASMC proliferation and pulmonary vascular remodeling in pulmonary arterial hypertension (PAH) model rats. Rats were divided into the following four groups: i) normoxia; ii) hypoxia (10% O₂); iii) treatment, hypoxia + intragastrical administration of AS‑IV (2 mg/kg) daily for 28 days; and iv) DAPT, hypoxia + AS‑IV treatment + subcutaneous administration of DAPT (10 mg/kg) three times daily. The effects of AS‑IV treatment on the development of hypoxia‑induced PAH, right ventricle (RV) hypertrophy and pulmonary vascular remodeling were examined. Furthermore, PASMCs were treated with 20 µmol/l AS‑IV under hypoxic conditions for 48 h. To determine the effect of Notch signaling in vascular remodeling and the potential mechanisms underlying AS‑IV treatment, 5 mmol/l γ‑secretase inhibitor [N‑[N‑(3,5‑difluorophenacetyl)‑L‑alanyl]‑S‑phenylglycine t‑butyl ester (DAPT)] was used. Cell viability and apoptosis were determined by performing the MTT assay and flow cytometry, respectively. Immunohistochemistry was conducted to detect the expression of proliferating cell nuclear antigen (PCNA). Moreover, the mRNA and protein expression levels of Notch‑3, Jagged‑1, hes family bHLH transcription factor 5 (Hes‑5) and PCNA were measured via reverse transcription‑quantitative PCR and western blotting, respectively. Compared with the normoxic group, hypoxia‑induced PAH model rats displayed characteristics of PAH and RV hypertrophy, whereas AS‑IV treatment alleviated PAH and prevented RV hypertrophy. AS‑IV also inhibited hypoxia‑induced pulmonary vascular remodeling, as indicated by reduced wall thickness and increased lumen diameter of pulmonary arterioles, and decreased muscularization of distal pulmonary vasculature in hypoxia‑induced PAH model rats. Compared with normoxia, hypoxia promoted PASMC proliferation in vitro, whereas AS‑IV treatment inhibited hypoxia‑induced PASMC proliferation by downregulating PCNA expression in vitro and in vivo. In hypoxia‑treated PAH model rats and cultured PASMCs, AS‑IV treatment reduced the expression levels of Jagged‑1, Notch‑3 and Hes‑5. Furthermore, Notch signaling inhibition via DAPT significantly inhibited the pulmonary vascular remodeling effect of AS‑IV in vitro and in vivo. Collectively, the results indicated that AS‑IV effectively reversed hypoxia‑induced pulmonary vascular remodeling and PASMC proliferation via the Notch signaling pathway. Therefore, the present study provided novel insights into the mechanism underlying the use of AS‑IV for treatment of vascular diseases, such as PAH.

View Figures

View References

1	Sakao S: Chronic obstructive pulmonary disease and the early stage of cor pulmonale: A perspective in treatment with pulmonary arterial hypertension-approved drugs. Respir Investig. 57:325–329. 2019. View Article : Google Scholar
2	Samareh Fekri M, Torabi M, Azizi Shoul S and Mirzaee M: Prevalence and predictors associated with severe pulmonary hypertension in COPD. Am J Emerg Med. 36:277–280. 2018. View Article : Google Scholar
3	Rowan SC, Keane MP, Gaine S and McLoughlin P: Hypoxic pulmonary hypertension in chronic lung diseases: Novel vasoconstrictor pathways. Lancet Respir Med. 4:225–236. 2016. View Article : Google Scholar
4	Bunel V, Guyard A, Dauriat G, Danel C, Montani D, Gauvain C, Thabut G, Humbert M, Castier Y, Dorfmüller P and Mal H: Pulmonary arterial histologic lesions in patients with COPD with severe pulmonary hypertension. Chest. 156:33–44. 2019. View Article : Google Scholar
5	Sauler M, Fares WH and Trow TK: Standard nonspecific therapies in the management of pulmonary arterial hypertension. Clin Chest Med. 34:799–810. 2013. View Article : Google Scholar
6	Shimoda LA, Yun X and Sikka G: Revisiting the role of hypoxia-inducible factors in pulmonary hypertension. Curr Opin Physiol. 7:33–40. 2019. View Article : Google Scholar
7	Liu S, Shergis J, Chen X, Yu X, Guo X, Zhang AL, Lu C and Xue CC: Chinese herbal medicine (weijing decoction) combined with pharmacotherapy for the treatment of acute exacerbations of chronic obstructive pulmonary disease. Evid Based Complement Alternat Med. 2014:2570122014. View Article : Google Scholar
8	Ren S, Zhang H, Mu Y, Sun M and Liu P: Pharmacological effects of Astragaloside IV: A literature review. J Tradit Chin Med. 33:413–416. 2013. View Article : Google Scholar
9	Yuan X, Sun S, Wang S and Sun Y: Effects of astragaloside IV on IFN-gamma level and prolonged airway dysfunction in a murine model of chronic asthma. Planta Med. 77:328–333. 2011. View Article : Google Scholar
10	Leng B, Tang F, Lu M, Zhang Z, Wang H and Zhang Y: Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Life Sci. 209:111–121. 2018. View Article : Google Scholar
11	Chen Z, Cai Y, Zhang W, Liu X and Liu S: Astragaloside IV inhibits platelet-derived growth factor-BB-stimulated proliferation and migration of vascular smooth muscle cells via the inhibition of p38 MAPK signaling. Exp Ther Med. 8:1253–1258. 2014. View Article : Google Scholar
12	Song Z, Wei D, Chen Y, Chen L, Bian Y, Shen Y, Chen J and Pan Y: Association of astragaloside IV-inhibited autophagy and mineralization in vascular smooth muscle cells with lncRNA H19 and DUSP5-mediated ERK signaling. Toxicol Appl Pharmacol. 364:45–54. 2019. View Article : Google Scholar
13	Spiekerkoetter E, Goncharova EA, Guignabert C, Stenmark K, Kwapiszewska G, Rabinovitch M, Voelkel N, Bogaard HJ, Graham B, Pullamsetti SS and Kuebler WM: Hot topics in the mechanisms of pulmonary arterial hypertension disease: Cancer-like pathobiology, the role of the adventitia, systemic involvement, and right ventricular failure. Pulm Circ. 9:20458940198897752019. View Article : Google Scholar
14	Wang X, Xiao D, Ma C, Zhang L, Duan Q, Zheng X, Mao M, Zhu D and Li Q: The effect of honokiol on pulmonary artery endothelium cell autophagy mediated by cyclophilin A in hypoxic pulmonary arterial hypertension. J Pharmacol Sci. 139:158–165. 2019. View Article : Google Scholar
15	Wang S, Cao W, Gao S, Nie X, Zheng X, Xing Y, Chen Y, Bao H and Zhu D: TUG1 regulates pulmonary arterial smooth muscle cell proliferation in pulmonary arterial hypertension. Can J Cardiol. 35:1534–1545. 2019. View Article : Google Scholar
16	Borggrefe T, Lauth M, Zwijsen A, Huylebroeck D, Oswald F and Giaimo BD: The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFβ/BMP and hypoxia pathways. Biochim Biophys Acta. 1863:303–313. 2016. View Article : Google Scholar
17	Bigas A and Espinosa L: The multiple usages of Notch signaling in development, cell differentiation and cancer. Curr Opin Cell Biol. 55:1–7. 2018. View Article : Google Scholar
18	Wang Y, Dai S, Cheng X, Prado E, Yan L, Hu J, He Q, Lv Y, Lv Y and Du L: Notch3 signaling activation in smooth muscle cells promotes extrauterine growth restriction-induced pulmonary hypertension. Nutr Metab Cardiovasc Dis. 29:639–651. 2019. View Article : Google Scholar
19	Harrison OJ, Visan AC, Moorjani N, Modi A, Salhiyyah K, Torrens C, Ohri S and Cagampang FR: Defective NOTCH signaling drives increased vascular smooth muscle cell apoptosis and contractile differentiation in bicuspid aortic valve aortopathy: A review of the evidence and future directions. Trends Cardiovasc Med. 29:61–68. 2019. View Article : Google Scholar
20	Yu YR, Mao L, Piantadosi CA and Gunn MD: CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 48:647–654. 2013. View Article : Google Scholar
21	Song Y, Zhang Y, Jiang H, Zhu Y, Liu L, Feng W, Yang L, Wang Y and Li M: Activation of Notch3 promotes pulmonary arterial smooth muscle cells proliferation via Hes1/p27Kip1 signaling pathway. FEBS Open Bio. 5:656–660. 2015. View Article : Google Scholar
22	Chen X, Yao JM, Fang X, Zhang C, Yang YS, Hu CP, Chen Q and Zhong GW: Hypoxia promotes pulmonary vascular remodeling via HIF-1α to regulate mitochondrial dynamics. J Geriatr Cardiol. 16:855–871. 2019.
23	Yu X, Li T, Liu X, Yu H, Hao Z, Chen Y, Zhang C, Liu Y, Li Q, Mao M and Zhu D: Modulation of pulmonary vascular remodeling in hypoxia: Role of 15-LOX-2/15-HETE-MAPKs pathway. Cell Physiol Biochem. 35:2079–2097. 2015. View Article : Google Scholar
24	Crnkovic S, Marsh LM, El Agha E, Voswinckel R, Ghanim B, Klepetko W, Stacher-Priehse E, Olschewski H, Bloch W, Bellusci S, et al: Resident cell lineages are preserved in pulmonary vascular remodeling. J Pathol. 244:485–498. 2018. View Article : Google Scholar
25	Yan J, Chen R, Liu P and Gu Y: Docosahexaenoic acid inhibits development of hypoxic pulmonary hypertension: In vitro and in vivo studies. Int J Cardiol. 168:4111–4116. 2013. View Article : Google Scholar
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
27	Roels S, Tilmant K, Van Daele A, Van Marck E and Ducatelle R: Proliferation, DNA ploidy, p53 overexpression and nuclear DNA fragmentation in six equine melanocytic tumours. J Vet Med A Physiol Pathol Clin Med. 47:439–48. 2000. View Article : Google Scholar
28	Heidebrecht F, Heidebrecht A, Schulz I, Behrens SE and Bader A: Improved semiquantitative western blot technique with increased quantification range. J Immunol Methods. 345:40–48. 2009. View Article : Google Scholar
29	Yang C, Mo Y, Xu E, Wen H, Wei R, Li S, Zheng J, Li W, Le B, Chen Y, et al: Astragaloside IV ameliorates motor deficits and dopaminergic neuron degeneration via inhibiting neuroinflammation and oxidative stress in a Parkinson's disease mouse model. Int Immunopharmacol. 75:1056512019. View Article : Google Scholar
30	Du J, Liu J, Zhen J, Yang ST, Zheng EL and Leng JY: Astragaloside IV protects cardiomyocytes from hypoxia-induced injury by down-regulation of lncRNA GAS5. Biomed Pharmacother. 116:1090282019. View Article : Google Scholar
31	Liu ZH, Liu HB and Wang J: Astragaloside IV protects against the pathological cardiac hypertrophy in mice. Biomed Pharmacother. 97:1468–1478. 2018. View Article : Google Scholar
32	Yao Y, Li H, Da X, He Z, Tang B, Li Y, Hu C, Xu C, Chen Q and Wang QK: SUMOylation of Vps34 by SUMO1 promotes phenotypic switching of vascular smooth muscle cells by activating autophagy in pulmonary arterial hypertension. Pulm Pharmacol Ther. 55:38–49. 2019. View Article : Google Scholar
33	Zhang DQ, Li JS, Zhang YM, Gao F and Dai RZ: Astragaloside IV inhibits Angiotensin II-stimulated proliferation of rat vascular smooth muscle cells via the regulation of CDK2 activity. Life Sci. 105–109. 2018. View Article : Google Scholar
34	Gu L, Tao X, Xu Y, Han X, Qi Y, Xu L, Yin L and Peng J: Dioscin alleviates BDL- and DMN-induced hepatic fibrosis via Sirt1/Nrf2-mediated inhibition of p38MAPK pathway. Toxicol Appl Pharmacol. 2921:19–29. 2016. View Article : Google Scholar
35	Liu D, Chen L, Zhao H, Vaziri ND, Ma SC and Zhao YY: Small molecules from natural products targeting the Wnt/β-catenin pathway as a therapeutic strategy. Biomed Pharmacother. 117:1089902019. View Article : Google Scholar
36	Wang SG, Xu Y, Chen JD, Yang CH and Chen XH: Astragaloside IV stimulates angiogenesis and increases nitric oxide accumulation via JAK2/STAT3 and ERK1/2 pathway. Molecules. 18:12809–12819. 2013. View Article : Google Scholar
37	Kostina A, Semenova D, Kostina D, Uspensky V, Kostareva A and Malashicheva A: Human aortic endothelial cells have osteogenic Notch-dependent properties in co-culture with aortic smooth muscle cells. Biochem Biophys Res Commun. 514:462–468. 2019. View Article : Google Scholar
38	Yamamura H, Yamamura A, Ko EA, Pohl NM, Smith KA, Zeifman A, Powell FL, Thistlethwaite PA and Yuan JX: Activation of Notch signaling by short-term treatment with Jagged-1 enhances store-operated Ca(2+) entry in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 306:C871–C878. 2014. View Article : Google Scholar
39	Zhang X, Chen J, Xu P and Tian X: Protective effects of Astragaloside IV against hypoxic pulmonary hypertension. Medchemcomm. 9:1715–1721. 2018. View Article : Google Scholar
40	Wang W, Liu J, Ma A, Miao R, Jin Y, Zhang H, Xu K, Wang C and Wang J: mTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3. J Cell Physiol. 229:2117–2125. 2014. View Article : Google Scholar
41	Liang C, Ni GX, Shi XL, Jia L and Wang YL: Astragaloside IV regulates the HIF/VEGF/Notch signaling pathway through miRNA-210 to promote angiogenesis after ischemic stroke. Restor Neurol Neurosci. 38:271–282. 2020.